Vaxart’s Business Progress and Financial Results Overview
Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company, recently provided a significant update on its business and reported its financial outcomes for the third quarter of 2025. This latest communication showcases exciting developments in their oral recombinant vaccine platform, which is designed to simplify vaccine delivery and storage.
Key Partnership with Dynavax
One of the most noteworthy achievements this quarter is Vaxart's exclusive license agreement with Dynavax Technologies. This collaboration is centered around Vaxart’s potential COVID-19 oral pill vaccine candidate. The deal could yield cumulative financial gains of up to $700 million, alongside royalties. The initial $25 million upfront payment and additional equity investment signify strong confidence from Dynavax, enhancing Vaxart’s financial foundation.
Enrollment Progress in Phase 2b COVID-19 Trial
As of now, Vaxart successfully completed enrollment of approximately 5,400 participants in a Phase 2b clinical trial investigating their oral COVID-19 vaccine. The topline data from this trial is expected in late 2026, offering invaluable insights into the safety and efficacy of this innovative therapeutic approach. Meanwhile, preliminary data from a smaller cohort is anticipated in the first quarter of 2026, ready to inform next steps in vaccine development.
Advancements in Norovirus Vaccine Development
In addition to its COVID-19 initiatives, Vaxart has made strides in developing its second-generation oral norovirus vaccine. Positive data was reported from the Phase 1 trial, which demonstrated substantial antibody responses, suggesting improved protection against infection. The company is actively seeking partnerships to further develop its norovirus vaccine, as well as its promising programs targeting HPV and influenza.
Financial Performance Amid Expansion
Vaxart reported substantial growth in revenue for the third quarter, reaching $72.4 million—an impressive increase from $4.9 million during the same period last year. This surge largely stems from government contracts related to their ongoing BARDA partnership. Conversely, total operating expenses escalated to $80.2 million due to the substantial investments in clinical trials, yet the company remains optimistic about the long-term trajectory.
Looking Ahead: Cash Position and Runway
As of September 30, 2025, Vaxart’s cash, cash equivalents, and investments stand at $28.8 million. With the recent financial influx from Dynavax, Vaxart expects its current cash runway to extend into the second quarter of 2027. This solid financial groundwork is enabling them to pursue further strategic alliances and explore funding opportunities that do not dilute shareholder value.
Upcoming Events and Investor Engagement
Vaxart will hold a conference call to discuss these recent updates in more detail, demonstrating their commitment to transparency with investors. Additionally, a live stockholder fireside chat is scheduled, which allows for direct engagement and the addressing of shareholder queries.
About Vaxart
Vaxart specializes in developing oral recombinant vaccines leveraging its proprietary delivery platform. Their innovative approach involves combining ease of storage with effective vaccination strategies, aiming to overcome challenges associated with traditional vaccine methods. Vaxart is focused on vaccines for significant health concerns, including COVID-19, norovirus, and HPV, representing a key player in the ongoing evolution of vaccine technology.
Frequently Asked Questions
What recent partnership has Vaxart made?
Vaxart entered into an exclusive license agreement with Dynavax Technologies for its COVID-19 oral vaccine candidate, potentially worth up to $700 million.
What is the status of Vaxart’s COVID-19 vaccine trial?
Vaxart has completed enrollment for a Phase 2b trial involving approximately 5,400 participants, with topline data expected in late 2026.
How did Vaxart's revenue change this quarter?
Revenue for Q3 2025 reached $72.4 million, significantly up from $4.9 million during the same time last year, driven largely by government contracts.
What are Vaxart's future plans for its vaccines?
Vaxart is looking to further develop its COVID-19 and norovirus vaccine programs while exploring partnership opportunities to enhance growth.
How much cash does Vaxart currently hold?
As of the end of September 2025, Vaxart reported $28.8 million in cash and equivalents, with a runway extended into the second quarter of 2027.
